stroke, 4 (2.4%) had frequent pain, and 3 (1.8%) had recurrent ACS. There was no relationship between the early clinical predictors and later adverse outcomes, with the possible exception of leukocyte count. Most subjects who experienced adverse events were predicted to be at low risk for adverse events. No subject who was predicted to be at high risk actually experienced an adverse outcome. The sensitivity of the model did not rise above 20% until specificity fell below 60%. We suggest that this model should not be used as a criterion to initiate early interventions for sickle cell disease.
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INTRODUCTION
Sickle cell anemia (SS), the homozygous form of sickle cell disease (SCD), has protean manifestations that are mostly unpredictable. 1 Therefore, it has been difficult to identify young children with SS who are at highest risk of adverse outcomes before their irreversible organ damage has occurred. A robust predictive model would allow early, tailored therapy to prevent adverse outcomes. Transcranial Doppler ultrasonography is an example of a successful screening tool that can identify children with SS at high risk of stroke. 2 TCD screening in conjunction with directed chronic transfusion programs has begun to decrease the incidence of stroke. 3 Besides stroke, the other serious complications of SCD are difficult to predict in individual patients. 1 As such, clinicians often wait for children to manifest severe disease before initiating treatments like hydroxyurea, chronic transfusions, or stem cell transplantation.
To address this challenge, the Cooperative Study of Sickle Cell Disease (CSSCD) developed a model to predict severe disease in its infant cohort. 4 Severe disease was defined as one of four adverse outcomes: death, stroke, frequent pain, or recurrent acute chest syndrome (ACS). The probability of experiencing one of these adverse outcomes by 10 years of age could be predicted by a multivariable model that included the following predictors: dactylitis in the first year of life ("early dactylitis"), the mean steady-state hemoglobin (Hgb) concentration in the second year of life, and the mean steady-state leukocyte count in the second year of life. The CSSCD infant cohort accrued patients from 1978 to 1988, which was before both newborn screening and prophylactic penicillin were universal and when fatal bacterial sepsis was more common than it is now. Indeed, after stroke, death was the second most frequently predicted adverse outcome. The CSSCD early prediction model has not been validated in other cohorts, so we wished to test its performance in a contemporary SCD cohort. The Dallas Newborn Cohort (DNC) is a large, single-center newborn inception cohort that is independent of the CSSCD. 5 The rate of fatal bacterial sepsis in the DNC is low because of universal newborn screening, prophylactic penicillin, and recent use of the heptavalent conjugated pneumococcal vaccine. We previously showed that painful events, including dactylitis, in the first three years of life had limited prognostic utility for adverse outcomes in the DNC. 6 However, unlike the CSSCD, we did not restrict the analysis of dactylitis to episodes in the first year of life, and we did not study laboratory markers. 6 Therefore, we sought to test the performance of the multivariable CSSCD model. We hypothesized that it did not predict adverse outcomes in the DNC.
PATIENTS AND METHODS

Overview
This is a retrospective cohort study in which the CSSCD early prediction model was applied to the DNC. The CSSCD model has not been used to direct therapy for members of the DNC.
Subjects
The Dallas Newborn Cohort
This newborn inception cohort includes patients with the four common SCD genotypes: 
Definitions and Measurements
Early Predictors
The same three predictors of adverse outcomes used in the CSSCD predictive model were studied here: (1) 
Adverse Outcomes
The same four adverse outcomes predicted in the CSSCD infant cohort were studied here: (1) 1 episode/year for 3 consecutive years). 4 However, we considered only hospitalizations for pain in this analysis, unlike the CSSCD, because we do not systematically track episodes of pain treated only at home or in outpatient facilities (e.g., emergency rooms or clinics). Outcomes were identified by query of the database and review of selected medical records. If a subject experienced more than one adverse outcome, only the first adverse outcome was considered. Only episodes of pain or ACS that occurred before the start of any disease-modifying therapy (hydroxyurea, chronic transfusions, or stem cell transplantation) were included, because such treatments usually alter their natural frequency. If the reason for any single hospitalization was recorded in the database as both a painful event and ACS (e.g., painful event complicated by ACS), the hospitalization was counted as an episode of ACS only because ACS was considered to be the more severe complication. ACS is defined clinically in our center as an acute pulmonary illness that is characterized by a new radiographic pulmonary infiltrate and some combination of fever, hypoxemia, thoracic pain, and signs and symptoms of respiratory illness.
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Length of Follow-Up
We calculated the length of follow-up for each subject as the time from study entry (the first visit in our center) until the end of study (February 9, 2005) or, if the patient was lost to follow-up, until the date of last clinical visit in our center. Follow-up time was also truncated at the first occurrence of any of the following: death; clinically overt stroke; criteria being met for frequent pain or recurrent ACS; initiation of hydroxyurea or chronic transfusions; or stem cell transplantation.
Statistical Analysis
Univariate Analyses
We first examined the relationships between the three individual predictors and the composite of adverse outcomes. For early dactylitis and severe anemia we used the Fisher exact test and odds ratios (OR). For leukocyte count we used a 2-sided t-test for equality of means (equal variances not assumed) and calculated a mean difference and a 95% confidence interval (95% CI). 
Multivariate Analyses
We then calculated the expected probability of an adverse outcome for each DNC subject with the logistic regression equation used to predict adverse outcomes in the CSSCD infant cohort. This equation includes the following covariates: follow-up time, early dactylitis (yes or no), severe anemia (yes or no), and mean steady-state leukocyte count (continuous) in the second year of life. The parameter estimates for this predictive model were provided through personal communication with CSSCD investigators (S.T.
Miller and L.A. Sleeper). The predicted probabilities from this calculation were classified according to CSSCD definitions as "low risk" (probabilities < 0.09), "medium risk" (0.09 to 0.35), or "high risk" (≥0.36). We then compared the predicted and the observed outcomes in the DNC. A receiver-operating characteristic (ROC) curve was generated to describe the relationship between the calculated probability variable and the observed outcome. We also used the Cox proportional hazards method to model the time to occurrence of an adverse outcome while controlling for the following baseline covariates: early dactylitis (dichotomous), hemoglobin concentration (continuous), and total leukocyte count (continuous).
Data were analyzed using SPSS 13.0 statistical software (SPSS Inc., Chicago, IL, USA). P-values < 0.05 were considered statistically significant. We did not adjust for multiple comparisons.
RESULTS
Characteristics of Subjects
We identified 206 subjects who met the inclusion criteria. Thirty-eight were ineligible for the following reasons: 14 had no clinical visits in the second year of life; 4 had no clinic visits while in steady-state; 3 were treated as infants with BABY HUG study medicine, which may have been hydroxyurea; 2 were begun on chronic transfusions before 2 years of age; and 15 had incomplete medical records. The remaining 168 children provided 1,188 patient-years of follow-up. Ninety-two were male and 76 were female; 163 had SS and 5 had Sβ 0 . Table 1 shows ages and hematologic data. Table 2 shows the frequency of the occurrence of the early predictors, both individually and in the combinations that conferred a high probability of an adverse outcome at 10 years of age in the CSSCD infant cohort. 4 The 4 subjects who had high-risk combinations had a mean follow-up of 9.7 years (median 12). Table 3 Two subjects experienced two adverse events each. One had a stroke at 2 years of age, and he died from complications of recurrent strokes at 7 years of age. The second had a stroke a 6 years of age, and she also met the criteria for recurrent ACS at the time chronic transfusions were begun. We considered only these two patients' initial overt strokes for purposes of this analysis.
The frequency of adverse events among the 38 ineligible subjects was not different than the 168 eligible subjects (data not shown). We also found there to be neither a significant association (P=0.182) between the time period of analysis and the rate of adverse outcomes nor a trend for a difference (P=0.108) (data not shown), so it is reasonable to assume that the rate of adverse outcomes was constant throughout the study period.
For
Ten subjects were treated with hydroxyurea, of whom only 3 met the strict CSSCD criteria for an adverse event (frequent pain) before starting therapy. Fifteen were treated with chronic transfusions, of whom 14 met CSSCD criteria for an adverse event before starting therapy (13 had stroke; 1 had frequent pain). One subject underwent stem cell transplantation because of overt stroke.
Performance of the Model
Univariate Analyses
The occurrence of early dactylitis was not associated with adverse outcomes: 13.8% of subjects with early dactylitis had an adverse outcome compared to 13 
Multivariate Analyses
The predicted probabilities of adverse outcomes for DNC subjects, calculated by the CSSCD logistic regression equation, ranged from 0.01 to 0.52 (mean 0.11; median 0.07). In the DNC, 57.1% were predicted to be "low risk", 38.7% were "medium risk", and 4.2% were "high risk". This compares to a distribution in the CSSCD of 44%, 53%, and 3%, respectively. 4 Fifteen (16.3%) "low risk" and 8 (12.3%) "medium risk" DNC For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 11 subjects had adverse outcomes. None of the 7 DNC subjects who were classified as "high risk" actually experienced an adverse outcome as defined by the CSSCD criteria.
One of these 7 subjects began treatment with hydroxyurea at 12.5 years of age for recurrent painful events. His pre-hydroxyurea rates of pain and ACS were 0.96 and 0.32 hospitalizations/year, respectively. The remaining 6 subjects with a mean follow-up of In the Cox proportional hazards model, the omnibus test of model coefficients was not significant (P = 0.068). Early dactylitis (P = 0.548), hemoglobin concentration (P = 0.140) and total leukocyte count (P = 0.089) were not significant predictors of the time to an adverse outcome.
DISCUSSION
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We found that the CSSCD early prediction model was not better than random prediction in the DNC. Most subjects who experienced adverse events were predicted to be at low risk for adverse events. No subject who was predicted to be at high risk actually experienced an adverse outcome. One component of the CSSCD model, the total leukocyte count in the second year of life, was modestly associated with adverse outcomes in univariate analysis, but not in the Cox proportional hazards model.
Leukocytes are known to be involved in the process of vaso-occlusion, 8 and leukocytosis in adults is associated with an increased frequency of acute chest syndrome 9 and stroke. 10 As such, early leukocytosis could also be an indicator of an individual's tendency for more frequent vaso-occlusion throughout life. The two other components of the model, early dactylitis and hemoglobin concentration in the second year of life, were not predictive of outcomes in either the univariate or multivariate analyses. We conclude that the model is not clinically useful, at least in the DNC. There are no publications that report a direct test of the CSSCD model in other cohorts, so a comparison of results across several cohorts cannot be made.
It is notable that we found no association between severe anemia and later adverse outcomes. This could simply be the consequence of the small number of DNC subjects who had severe anemia (N=5). However, in accordance with the CSSCD model, we used Hgb concentration as a dichotomous predictor (Hgb <7 g/dL or not) and considered only values from the second year of life. These restrictions certainly decreased the potential power of this variable as a predictor. Moreover, other studies have shown that steady-state Hgb concentration has contrasting features as a predictor:
low values are associated with death 11, 12 and stroke, 10 and high values are associated with pain 13 and ACS. 9 So, using a low value of Hgb concentration (Hgb < 7 g/dL) to predict all four adverse outcomes is likely to be problematic and yield different results in different analyses.
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Our study has a number of limitations. First, unlike the CSSCD, DNC subjects and families were not systematically questioned about the occurrence of painful events (other than dactylitis) that were managed entirely at home or in outpatient facilities (e.g., emergency rooms or clinics). We considered only painful events that required hospitalization. This could have resulted in misclassification, thereby reducing the performance of the model. For example, we treated 7 subjects with hydroxyurea who did not meet the strict CSSCD criteria for frequent pain or recurrent ACS. Perhaps the inclusion of these subjects' outpatient-only events could have changed their classification. It is also possible that the CSSCD criteria are simply too strict, and we do not wait for this degree of disease severity to manifest before starting hydroxyurea.
Second, our rate of frequent pain and recurrent ACS was lower than the CSSCD. The CSSCD used very stringent criteria that very few of our patients happened to meet, perhaps because we could not include outpatient-only episodes of pain in our analysis.
Third, laboratory testing was not mandated by a protocol; instead, it was obtained according to routine clinical care and assembled retrospectively. Hematologic data were based on a median of 3 blood counts in the DNC and 4 in the CSSCD. So, some hematologic data may be missing or less representative than the data from the CSSCD. differ from CSSCD. Nevertheless, we found no optimal tradeoff between sensitivity and specificity for any calculated probability, and the area under the ROC curve was less than 0.5. The sensitivity of the model did not rise above 20% until the specificity fell below 60%. Perhaps an additional 2.9 years of follow-up in the DNC would have allowed time for additional adverse events to occur, thereby improving the performance of the model. However, we found that the mean time to an adverse event was 4.7 years (median 3.7, interquartile range 2.3 -6.0). Because 75% of the adverse events occurred in first 6 years of life, an additional 2.9 years of follow-up would be unlikely to substantively change our findings. Moreover, the mean follow-up of the CSSCD validation cohort was only 5.8 years. 4 The main strength of this study is the use of an independently assembled cohort to test a statistical model, which is rigorous epidemiologic practice. The CSSCD modelgenerating and validation cohorts were subsets of a single cohort. 
